Bli medlem
Bli medlem

Du är här


Prothena to Report Third Quarter 2016 Financial Results on November 1

2016 Financial Results on November 1

DUBLIN, Ireland, 2016-10-25 22:05 CEST (GLOBE NEWSWIRE) --
Prothena Corporation plc (Nasdaq:PRTA), a late-stage clinical biotechnology
company focused on the discovery, development and commercialization of novel
protein immunotherapies, will announce financial results for the third quarter
and first nine months of 2016 on November 1, 2016 after the close of the U.S.
financial markets.

Consistent with past practice, the Company will not be conducting a conference
call in conjunction with this financial results release on November 1.

About Prothena

Prothena Corporation plc is a global, late-stage clinical biotechnology company
seeking to fundamentally change the course of progressive diseases with its
clinical pipeline of novel therapeutic antibodies. Fueled by its deep
scientific understanding built over decades of research in protein misfolding
and cell adhesion — the root causes of many serious or currently untreatable
amyloid and inflammatory diseases — Prothena is establishing a fully integrated
research, development and commercial focus and has advanced several drug
candidates into clinical studies while pursuing discovery of additional novel
therapies. Our pipeline of antibody-based product candidates targets a number
of potential indications including AL amyloidosis (NEOD001), Parkinson's
disease and other related synucleinopathies (PRX002), inflammatory diseases,
including psoriasis and psoriatic arthritis (PRX003), and ATTR amyloidosis
(PRX004). For more information, please visit the company's website at


Investors: Tran Nguyen, CFO

Media: Ellen Rose, Head of Communications

Författare SSE

Tala om vad ni tycker

Tala om vad ni tycker

Ni är just nu inne på en betaversion av nya aktiespararna. Lämna gärna feedback på vad ni tycker i formuläret nedan.